Nuvalent Inc NUVL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EDT
16.04UNCH (UNCH)
Volume
4,915
Close
16.04quote price arrow down-0.37 (-2.25%)
Volume
70,984
52 week range
7.09 - 40.82
Loading...
  • Open16.13
  • Day High16.43
  • Day Low15.62
  • Prev Close16.41
  • 52 Week High40.82
  • 52 Week High Date09/13/21
  • 52 Week Low7.09
  • 52 Week Low Date05/19/22

Key Stats

  • Market Cap776.50M
  • Shares Out48.41M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-15.76

KEY STATS

  • Open16.13
  • Day High16.43
  • Day Low15.62
  • Prev Close16.41
  • 52 Week High40.82
  • 52 Week High Date09/13/21
  • 52 Week Low7.09
  • 52 Week Low Date05/19/22
  • Market Cap776.50M
  • Shares Out48.41M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-15.76

RATIOS/PROFITABILITY

  • EPS (TTM)-1.49
  • P/E (TTM)-10.80
  • Fwd P/E (NTM)-8.55
  • EBITDA (TTM)-66.226M
  • ROE (TTM)-64.05%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Nuvalent Inc

There is no recent news for this security.

Profile

MORE
Nuvalent, Inc. is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company is advancing a pipeline of product candidates with parallel programs in cancers driven by genomic alterations in the ROS proto-oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), along with multiple discovery-stage research programs. Its lead product candidate, NVL-520, is a ROS1-selective inhibitor designed to address the...
Anna Protopapas
Independent Chairman of the Board
James Porter Ph.D.
President, Chief Executive Officer, Director
Alexandra Balcom CPA
Chief Financial Officer, Treasurer
Address
One Broadway, 14th Floor
Cambridge, MA
02142
United States

Top Peers

SYMBOLLASTCHG%CHG
SAVA
Cassava Sciences Inc
25.58-0.89-3.36%
PNT
POINT Biopharma Global Inc
8.90+0.22+2.53%
CMPS
Compass Pathways PLC
15.77-1.84-10.45%
RAPT
Rapt Therapeutics Inc
26.69-1.00-3.61%
NKTX
Nkarta Inc
16.46-0.55-3.23%